Skip to main content
. 2017 Aug 7;7:7456. doi: 10.1038/s41598-017-07814-4

Figure 1.

Figure 1

Structures of compounds implemented in LRA screens and HIV reactivation studies herein. (a) HDAC inhibitors including SDL148 (largazole), two of its derivatives JMF1080 and SDL256, as well as, vorinostat (SAHA). (b) PKC modulators including bryostatin-1 and two of its analogs SUW133 and SUW124.